Free shipping on all orders over $ 500

Glembatumumab vedotin

Cat. No. M58984

All AbMole products are for research use only, cannot be used for human consumption.

Glembatumumab vedotin Structure
Synonym:

CDX-011; CR011-vcMMAE

Size Price Availability Quantity
100ug USD 480  USD480 In stock
1mg USD 1060  USD1060 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >99%, Endotoxin < 1 EU/µg
  • COA
  • MSDS
Biological Activity

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin binds to GPNMB on tumors, the complex is internalized and MMAE is released via proteolytic cleavage of the vc linker in a lysosomal compartment. Tumor cell death occurs as a result of microtubule inhibition by MMAE with resultant cell cycle arrest.

Immobilized human GPNMB His at 2 ug/mL can bind Glembatumumab vedotin, the EC50 is 0.05407 ug/mL.

Glembatumumab vedotin (CR011-vcMMAE; 1.25-80 mg/kg; i.v.; every 4 days; for 16 days) shows short-term anti-tumor effects (inhibition of tumor growth) and long-term effects (complete regression) in human SK-MEL-2 and SK-MEL-5 melanoma xenografts.

Chemical Information
CAS Number 1182215-65-1
Solubility (25°C) For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml.
Storage Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles.
Related Antibody-Drug Conjugates (ADCs) Products
Praluzatamab-MMAE

Praluzatamab-MMAE is an antibody-drug conjugate (ADC).

Oregovomab-MMAE

Oregovomab-MMAE is an antibody-drug conjugate (ADC).

Patritumab-MMAE

Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE.

Depatuxizumab mafodotin

Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII.

Ozuriftamab vedotin

Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE.

  Catalog
Abmole Inhibitor Catalog




Keywords: Glembatumumab vedotin, CDX-011; CR011-vcMMAE supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.